Fig. 5: Engineering Env through pseudotyping with viral envelope protein Vsv-g for extended in vitro targeting capabilities and Nab escaping.
From: Engineering a streamlined virus-like particle for programmable tissue-specific gene delivery
a Env was replaced by Vsv-g and packaging luciferase mRNA containing VLP (VLP.Vsv-g). b In vitro efficiency of VLP.Vsv-g on non-human primate PBMCs with increased VLP genomic copies per cell. NC, negative controls without fusogens. NC of Vsv-g, negative control for VLP.Vsv-g, A549 cells (SFV-Env vs. VLP.Vsv-g at 1000, 10,000, 100,000 copies per cell, ****P < 0.0001; two-way ANOVA with Tukey’s multiple comparison test). c In vitro efficiency of VLP.Vsv-g on mouse PBMCs with increased vector genomic copies per cell. NC, negative controls without fusogens. NC of Vsv-g, negative control for VLP.Vsv-g, A549 cells (SFV-Env vs. VLP.Vsv-g at 1000 copies per cell, *P = 0.015; at 10,000 copies per cell, ***P = 0.0001; at 100,000 copies per cell, ****P < 0.0001; two-way ANOVA with Tukey’s multiple comparison test). Serum neutralizing antibody evaluation against d SFV-Env and e VLP.Vsv-g in intravenously re-administered animals after the second injection. f Serum neutralizing antibody titers against SFV-Env and VLP.Vsv-g in animals after the second intravenous injection. ND not detected. All error bars represented the mean with standard deviation (SD) of three replicates. Source data are provided as a Source Data file.
